Spots Global Cancer Trial Database for advanced nsclc
Every month we try and update this database with for advanced nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | NCT03127449 | Advanced NSCLC | Alflutinib | 18 Years - | Allist Pharmaceuticals, Inc. | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients | NCT04229121 | Advanced NSCLC Circulating Tum... Circulating Tum... | nonintervention | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | NCT04043195 | Advanced NSCLC | Nivolumab Oxaliplatin Ipilimumab | 18 Years - | University of California, San Diego | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | NCT03215810 | Non-Small Cell ... Metastatic Non-... Squamous Cell C... Advanced NSCLC Adenosquamous C... Adenocarcinomas | Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer | NCT00328562 | Non-Small Cell ... | ZD1839 (Iressa) Thoracic Radiot... | 18 Years - | Thomas Jefferson University | |
| Maintenance Gemcitabine in the Chinese Advanced Lung Cancer | NCT01336192 | Non Small Cell ... | Gemcitabine Best supportive... | 18 Years - 80 Years | Tongji University | |
| Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | NCT04967079 | Non Small Cell ... | Trametinib Anlotinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). | NCT05219162 | Advanced NSCLC | Gene Profile ex... | 18 Years - | AstraZeneca | |
| Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC) | NCT00452244 | Lung Cancer | simvastatin gefitinib only | 18 Years - | National Cancer Center, Korea | |
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | NCT06356675 | Advanced NSCLC | Tislelizumab Anlotinib | 18 Years - 75 Years | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | |
| Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel | NCT01222312 | Non Small Cell ... | Cisplatin Oxaliplatin Docetaxel Docetaxel | 18 Years - | Krankenhaus Nordwest | |
| Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) | NCT04636775 | NSCLC Stage IV NSCLC, Recurren... | Microbiome | 18 Years - | University of Kansas Medical Center | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | NCT04690686 | Non Small Cell ... | LW-02 device im... LW-02 device im... LW-02 device im... | 18 Years - 75 Years | Immunicom Inc | |
| Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01) | NCT03074175 | Advanced Nsclc | radiotherapy | 18 Years - 75 Years | Xinqiao Hospital of Chongqing | |
| Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations | NCT04992858 | Advanced NSCLC | CT053PTSA | 18 Years - | Sunshine Lake Pharma Co., Ltd. | |
| Tarceva Italian Lung Optimization tRial | NCT00637910 | Non Small Cell ... | Erlotinib Docetaxel | 18 Years - | Fatebenefratelli and Ophthalmic Hospital | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | NCT05859217 | Lung Cancer NSCLC Stage IV Metastatic NSCL... Advanced NSCLC | Cabozantinib Atezolizumab | 18 Years - | University of Kansas Medical Center | |
| Maintenance Gemcitabine in the Chinese Advanced Lung Cancer | NCT01336192 | Non Small Cell ... | Gemcitabine Best supportive... | 18 Years - 80 Years | Tongji University | |
| Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | NCT05085054 | Non Small Cell ... | Osimertinib Mes... | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | NCT04043195 | Advanced NSCLC | Nivolumab Oxaliplatin Ipilimumab | 18 Years - | University of California, San Diego | |
| Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | NCT03062800 | Advanced Nsclc | Thalidomide pemetrexed cisplatin carboplatin | 18 Years - 70 Years | Qilu Hospital of Shandong University | |
| Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | NCT04967079 | Non Small Cell ... | Trametinib Anlotinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | NCT04846452 | Metastatic NSCL... Recurrent NSCLC Advanced Non-Sm... | Sintilimab + An... Sintilimab + An... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01) | NCT03074175 | Advanced Nsclc | radiotherapy | 18 Years - 75 Years | Xinqiao Hospital of Chongqing | |
| Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00682383 | Unresectable Lo... | Cisplatin; Etop... | 18 Years - 90 Years | Mt. Sinai Medical Center, Miami | |
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | NCT06356675 | Advanced NSCLC | Tislelizumab Anlotinib | 18 Years - 75 Years | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | NCT03127449 | Advanced NSCLC | Alflutinib | 18 Years - | Allist Pharmaceuticals, Inc. | |
| Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV | NCT01003964 | Non Small Cell ... | IP GP | 18 Years - | National Cancer Center, Korea | |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | NCT01932229 | NSCLC | Afatinib treatm... | - | Sheba Medical Center | |
| Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | NCT05777278 | Non-small Cell ... | Savolitinib Docetaxel | 18 Years - | The First Affiliated Hospital of Guangzhou Medical University | |
| POSITIVE - Study (Part III) Heidelberg | NCT02055508 | Advanced NSCLC First Line Trea... | Exercise Interv... Care-Management... | 18 Years - | German Cancer Research Center | |
| Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand | NCT01130961 | Lung Cancer | - | AstraZeneca | ||
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | NCT05859217 | Lung Cancer NSCLC Stage IV Metastatic NSCL... Advanced NSCLC | Cabozantinib Atezolizumab | 18 Years - | University of Kansas Medical Center | |
| Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC) | NCT00452244 | Lung Cancer | simvastatin gefitinib only | 18 Years - | National Cancer Center, Korea | |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer | NCT03445000 | Non-small Cell ... Non-small Cell ... Non-small Cell ... | Alectinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 | NCT01836575 | Non Small Cell ... | Pemetrexed Carboplatin | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | NCT04690686 | Non Small Cell ... | LW-02 device im... LW-02 device im... LW-02 device im... | 18 Years - 75 Years | Immunicom Inc | |
| Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer | NCT01438307 | Non-small Cell ... Stage IV NSCLC Metastatic NSCL... | Cabazitaxel-XRP... Cabazitaxel-XRP... | 19 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
